Skip to main content
SpringerLink
Log in

The role of urokinase-type plasminogen activator in aggressive tumor cell behavior

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The correlation between urokinase-type plasminogen activator (uPA) expression and tumor cell invasion and metastasis has been well documented. Urokinase converts the zymogen plasminogen to plasmin, a trypsin-like enzyme with broad substrate specificities. Net uPA activity is determined not only by the amount of the enzyme itself, but also by its state of activation and the amount of specific plasminogen activator inhibitors (PAIs) present. Both uPA and its substrate, plasminogen, can bind to cells via specific membrane-associated receptors. Expression of uPA, uPA receptor (uPAR), and PAIs is regulated by growth factors, oncogenes, and other effector molecules. In the present review we discuss the interactions of uPA with its receptor, inhibitors, and substrate and how these interactions influence malignant behavior. We also review recent reports in which investigators have used anti-catalytic antibodies and/or gene transfection to demonstrate that uPA is directly involved in tumor cell invasion and metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Liotta LA, Thorgeirsson UP, Garbisa S: Role of collagenases in tumor cell invasion. Cancer Metastasis Rev 1: 277–288, 1982

    Google Scholar 

  2. Mullins DE, Rohrlich ST: The role of proteinases in cellular invasiveness. Biochim Biophys Acta 695: 177–214, 1983

    Google Scholar 

  3. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139–266, 1985

    Google Scholar 

  4. Saksela O, Rifkin DB: Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 4: 93–126, 1988

    Google Scholar 

  5. Werb Z: Proteinases and matrix degradation. In: W. Kelly (ed) Textbook of Rheumatology, 3rd edition, pp 300–321, 1989

  6. Sloane BF, Robinson D, Honn KD: Role for cathepsin B and cystatins in tumor growth and progression. Biol Chem Hoppe Seyler 371: (suppl) 193–198, 1990

    Google Scholar 

  7. Carrel A: J Exp Med 15: 516–528, 1912

    Google Scholar 

  8. Fischer A: Beitrag zur Biologie der Gewebezellen. Eine vergleichend biologische Studie der normalen und malignen Gewebezellen in vitro. Arch Entwicklungsmech Org (Willhelm Roux) 104: 210–222, 1925

    Google Scholar 

  9. Fischer A: Mechanism of the proteolytic activity of malignant tissue cells. Nature 157: 442, 1946

    Google Scholar 

  10. Reich E: Activation of plasminogen: A general mechanism for producing localized extracellular proteolysis. In: Berlin RD (ed) Molecular Basis of Biological Degradative Processes. Academic Press, New York, 1978, pp 155–169

    Google Scholar 

  11. Quigley JP: Proteolytic enzymes of normal and malignant cells. In: Hynes RO (ed) Surfaces of Normal and Malignant Cells. John Wiley and Sons, Chichester, 1979, pp 247–285

    Google Scholar 

  12. Unkeless JC, Tobia A, Ossowski L, Quigley JP, Rifkin DB, Reich E: An enzymatic function associated with transformation of fibroblasts by oncogenic viruses I. Chick embryo fibroblast cultures transformed by avian RNA tumor viruses. J Exp Med 137: 85–111, 1973

    Google Scholar 

  13. Ossowski L, Unkeless JC, Tobia A, Quigley JP, Rifkin DB, Reich E: An enzymatic function associated with transformation of fibroblasts by oncogenic viruses II. Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J Exp Med 137: 112–126, 1973

    Google Scholar 

  14. Pollack R, Risser R, Conlon S, Rifkin D: Plasminogen activator production accompanies loss of anchorage regulation in transformation of primary rat embryo cells by Simian virus 40. Proc Natl Acad Sci USA 71: 4729–4796, 1974

    Google Scholar 

  15. Howett MK, High CS, Rapp F: Production of plasminogen activator by cells transformed by Herpesvirus. Cancer Res 38: 1075–1078, 1978

    Google Scholar 

  16. Gallimore PH, McDougall JK, Chen LB: In vitro traits of adenovirus transformed cell lines and their relevance to tumorigenicity in nude mice. Cell 10: 669–678, 1977

    Google Scholar 

  17. Jones PA, DeClerck YA: Destruction of extracellular matrices containing glycoproteins, elastin and collagen by metastatic human tumor cells. Cancer Res 40: 3222–3229, 1980

    Google Scholar 

  18. Liotta LA, Goldfarb RH, Brundage R, Siegal GP, Terranova V, Garbisa S: Effect of plasminogen activator, plasmin and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 41: 4629–4636, 1981

    Google Scholar 

  19. Sheela S, Barrett JC: In vitro degradation of radiolabeled, intact basement membrane mediated by cellular plasminogen activator. Carcinogenesis 3: 363–369, 1982

    Google Scholar 

  20. Fairbairn S, Gilbert R, Ojakian G, Schwimmer R, Quigley JP: The extracellular matrix of normal chick fibroblasts: Its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants. J Cell Biol 101: 1790–1798, 1985

    Google Scholar 

  21. Skriver L, Larsson L, Kielberg V, Nielsen LS, Andreasen PB, Kristensen P, Dano K: Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcimona. J Cell Biol 99: 753–758, 1984

    Google Scholar 

  22. Mott DM, Fabisch PH, Sani BP, Soroff S: Lack of correlation between fibrinolysis and the transformed state of cultured mammalian cells. Biochem Biophys Res Commun 61: 621–627, 1974

    Google Scholar 

  23. Wolf BA, Goldberg AR: Rous sarcoma virus-transformed fibroblasts having low levels of plasminogen activator. Proc Natl Acad Sci USA 73: 3613–3617, 1976

    Google Scholar 

  24. Montesano R, Drevon C, Kuroki T, Saint Vincent L, Handleman S, Sanford KK, DeFeo D, Weinstein IB: Test for malignant transformation of rat liver cells in culture: Cytology, growth in soft agar and production of plasminogen activators. J Natl Cancer Inst 59: 1651–1658, 1977

    Google Scholar 

  25. Barrett JC, Sheela S, Ohki K, Kakunaga T: Reexamination of the role of plasminogen activator production for growth in semisolid agar of neoplastic hamster cells. Cancer Res 40: 1438–1442, 1980

    Google Scholar 

  26. Whur P, Magudia M, Boston J, Lockwood J, Williams DC: Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay. Br J Cancer 42: 305–313, 1980

    Google Scholar 

  27. Markus G, Kohga S, Camiolo SM, Madeja JM, Ambrus JL, Karakousis C: Plasminogen activator in human malignant melanoma. J Natl Cancer Inst 72: 1213–1222, 1984

    Google Scholar 

  28. Ostrowski LE, Ahsan A, Suthar BP, Pagast P, Bain DL, Wong C, Patel A, Schultz RM. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res 46: 4121–4128, 1986

    Google Scholar 

  29. Persky B, Ostrowski LE, Pagast P, Ahsan A, Schultz RM: Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion. Cancer Res 46: 4129–4134, 1986

    Google Scholar 

  30. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 47: 487–498, 1986

    Google Scholar 

  31. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R: Effects of inhibitors of plasminogen activators, serine proteinases, and collagenase IV on the invasion of basement membrane by metastatic cells. Cancer Res 48: 3307–3312, 1988

    Google Scholar 

  32. Quigley JP, Gold L, Schwimmer R, Sullivan LM: Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc Natl Acad Sci USA 84: 2776–2780, 1987

    Google Scholar 

  33. Gold LI, Schwimmer R, Quigley JP: Human plasma fibronectin as a substrate for human urokinase. Biochem J 262: 529–534, 1989

    Google Scholar 

  34. Riccio A, Grimaldi G, Verde P, Sebastio G, Boast S, Blasi F: The human urokinase-plasminogen activator gene and its promoter. Nuc Acids Res 13: 2759–2771, 1985

    Google Scholar 

  35. Patthy L: Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 41: 657–663, 1985

    Google Scholar 

  36. Ossowski L, Belin D: Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin. Mol Cell Biol 5: 3552–3559, 1985

    Google Scholar 

  37. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res 49: 2533–2553, 1989

    Google Scholar 

  38. Boyd D: Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line. Cancer Res 49: 2427–2432, 1989

    Google Scholar 

  39. Boyd D, Brattain M: Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line. Cancer Res 49: 1948–1953, 1989

    Google Scholar 

  40. Keski-Oja J, Blasi F, Leof EB, Moses HL: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol 106: 451–459, 1988

    Google Scholar 

  41. Hunter T: 1985. Oncogenes and growth control. TIBS 10: 275–280, 1985

    Google Scholar 

  42. Weinberg RA: The action of oncogenes in the cytoplasm and nucleus. Science 230: 770–776, 1985

    Google Scholar 

  43. Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP, Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17-beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837–841, 1987

    Google Scholar 

  44. Ciardiello F, Valverius EM, Colucci-D'Amato GL, Kim N, Bassin RH, Salomon DS: Differential growth factor expression in transformed mouse NIH-3T3 cells. J Cell Biochem 42: 45–57, 1990

    Google Scholar 

  45. Cutry AF, Kinniburgh AJ, Twardzik DR, Wenner CE: Transforming growth factor alpha (TGFα) induction of c-fos and c-myc expression in C3H 10T1/2 cells. Biochem Biophys Res Commun 152: 216–222, 1988

    Google Scholar 

  46. Lau LF, Nathans D: Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: Coordinate regulation with c-fos or c-myc. Proc Natl Acad Sci USA 84: 1182–1186, 1987

    Google Scholar 

  47. Goldfarb RH, Quigley JP: Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts. Cancer Res 38: 4601–4609, 1976

    Google Scholar 

  48. Bell SM, Brackenbury RW, Leslie ND, Degen JL: Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J Biol Chem 265: 1333–1338, 1990

    Google Scholar 

  49. Sullivan LM, Quigley JP: An anticatalytic monoclonal antibody to avian plasminogen activator: Its effect on behavior of RSV-transformed chick fibroblasts. Cell 45: 905–915, 1986

    Google Scholar 

  50. Garbisa S, Pozatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G, Liotta LA: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-E1a. Cancer Res 47: 1523–1528, 1987

    Google Scholar 

  51. Testa JE, Medcalf RL, Cajot J-F, Schleuning W-D, Sordat B: Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. Int J Cancer 43: 816–822, 1989

    Google Scholar 

  52. Brunner G, Pohl J, Erkell LJ, Radler-Pohl A, Schirrmacher V: Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene. J Cancer Res Clin Oncol 115: 139–144, 1989

    Google Scholar 

  53. Cohen RL, Niclas J, Lee WMF, Wun T-C, Crowley CW, Levinson AD, Sadler JE, Shuman MA: Effects of cellular transformation on expression of plasminogen activator inhibitors 1 and 2. J Biol Chem 264: 8375–8383, 1989

    Google Scholar 

  54. Muschel R, Liotta L: Role of oncogenes in metastasis. Carcinogesis 9: 705–710, 1988

    Google Scholar 

  55. Pohl J, Radler-Pohl A, Franks LM, Schirrmacher V: Analysis of metastasis competence of mouse bladder carcinoma cells after transfection with activated Ha-ras or N-ras oncogenes. J Cancer Res Clin Oncol 114: 373–379, 1988

    Google Scholar 

  56. Taniguchi S, Kawano T, Mitsudomi T, Kimura G, Baba T: fos oncogene transfer to a transformed rat fibroblast cell line enhances spontaneous lung metastasis in rat. Jpn J Cancer Res 77: 1193–1197, 1986

    Google Scholar 

  57. Pohl J, Goldfinger N, Radler-Pohl A, Rotter V, Schirrmacher V: p53 increases experimental metastatic capacity of murine carcinoma cells. Mol Cell Biol 8: 2078–2081, 1988

    Google Scholar 

  58. Egan SE, Wright JA, Jarolim L, Yanagihara K, Bassin RH, Greenberg AH: Transformation by oncogenes encoding protein kinases induces the metastatic phenotype. Science 238: 202–205, 1987

    Google Scholar 

  59. Kruithof EKO: Plasminogen activator inhibitors — A review. Enzyme 40: 113–121, 1988

    Google Scholar 

  60. Loskutoff DJ, Sawdey M, Mimuro J: Type 1 plasminogen activator inhibitor. Prog Hemostasis Thromb 9: 87–116, 1988

    Google Scholar 

  61. Shaw G, Kamen R: A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 46: 659–667, 1986

    Google Scholar 

  62. Pollanen J, Saksela O, Salonen E-M, Andreasen P, Nielsen L, Dano K, Vaheri A: Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 104: 1085–1096, 1987

    Google Scholar 

  63. Mimuro J, Loskutoff DJ: Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 264: 5058–5063, 1989

    Google Scholar 

  64. Declerck PJ, DeMol M, Alessi M-C, Baudner S, Paques E-P, Preissner KT, Muller-Berghaus G, Collen D: Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 263: 15454–15461, 1988

    Google Scholar 

  65. Mimuro J, Loskutoff DJ: Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. J Biol Chem 264: 936–939, 1989

    Google Scholar 

  66. Salonen E-M, Vaheri A, Pollanen J, Stephens R, Andreasen P, Mayer M, Dano K, Gailit J, Ruoslahti E: Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 264: 6339–6343, 1989

    Google Scholar 

  67. Laiho M, Saksela O, Keski-Oja J: Transforming growth factor-beta induction of type-1 plasminogen activator inhibitor. J Biol Chem 262: 17467–17474, 1987

    Google Scholar 

  68. Mimuro J, Schleef RR, Loskutoff DJ: Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70: 721–728, 1987

    Google Scholar 

  69. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN: Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 68: 1–19, 1990

    Google Scholar 

  70. Prendergast GC, Diamond LE, Dahl D, Cole MD: The c-myc-regulated gene mr1 encodes plasminogen activator inhibitor 1. Mol Cell Biol 10: 1265–1269, 1990

    Google Scholar 

  71. Astedt B, Lecander I, Ny T: The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1: 203–208, 1987

    Google Scholar 

  72. Wohlwend A, Belin D, Vassalli J-D: Plasminogen activator-specific inhibitors produced by human monocytes/macrophages. J Exp Med 165: 320–339, 1987

    Google Scholar 

  73. Belin D, Wohlwend A, Schleuning W-D, Kruithof EKO, Vassalli JD: Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activator inhibitor 2. EMBO J 8: 3287–3294, 1989

    Google Scholar 

  74. Pollanen J, Vaheri A, Tapiovaara H, Riley E, Bertram K, Woodrow G, Stephens RW: Prourokinase activation on the surface of human rhabdomyosarcoma cells: Localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor. Proc Natl Acad Sci USA 87: 2230–2234, 1990

    Google Scholar 

  75. McGuire PG, Seeds NW: The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells. J Cell Biochem 40: 215–227, 1989

    Google Scholar 

  76. Geiger M: Protein C inhibitor/plasminogen activator inhibitor 3. Fibrinolysis 2: 183–188, 1988

    Google Scholar 

  77. Wagner SL, Lau AL, Cunningham DD: Binding of protease nexin-1 to the fibroblast surface alters its target proteinase specificity. J Biol Chem 264: 611–615, 1989

    Google Scholar 

  78. Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F, Assoian RK: Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82: 4939–4943, 1985

    Google Scholar 

  79. Vassalli J-D, Baccino D, Belin D: A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100: 86–92, 1985

    Google Scholar 

  80. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G, Blasi F: The receptor-binding sequence of urokinase. A biological function for the growth factor module of proteases. J Biol Chem 262: 4437–4440, 1987

    Google Scholar 

  81. Miles LA, Dahlberg CM, Levin EG, Plow EF: Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells. Biochemistry 28: 9337–9343, 1989

    Google Scholar 

  82. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73–84, 1988

    Google Scholar 

  83. Estreicher A, Wohlwend A, Belin D, Schleuning W-D, Vassalli J-D: Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 264: 1180–1189, 1989

    Google Scholar 

  84. Picone R, Kajtaniak EL, Nielsen LS, Behrendt N, Mastronicola MR, Cubellis MV, Stoppelli MP, Pedersen S, Dano K, Blasi F: Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J Cell Biol 108: 693–702, 1989

    Google Scholar 

  85. Behrendt N, Ronne E, Plough M, Petri T, Lober D, Nielsen LS, Schleuning W-D, Blasi F, Appella E, Dano K: The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265: 6453–6464, 1990

    Google Scholar 

  86. Kirchheimer JC, Nong Y-H, Remold HG: IFN-gamma, tumor necrosis factor-alpha, and urokinase regulate the expression of urokinase receptors on human monocytes. J Immunol 141: 4229–4234, 1988

    Google Scholar 

  87. Kirchheimer JC, Wojta J, Christ G, Binder BR: Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J 1: 125–128, 1987

    Google Scholar 

  88. Kirchheimer JC, Christ G, Binder BR: Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 181: 103–107, 1989

    Google Scholar 

  89. Kirchheimer JC, Wojta J, Christ G, Binder BR: Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line. Proc Natl Acad Sci USA 86: 5424–5428, 1989

    Google Scholar 

  90. Sato Y, Rifkin DB: Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta-1-like molecule by plasmin during co-culture. J Cell Biol 109: 309–315, 1989

    Google Scholar 

  91. Burtin P, Fondaneche M-C: Receptor for plasmin on human carcinoma cells. J Natl Cancer Inst 80: 762–765, 1988

    Google Scholar 

  92. Miles LA, Plow EF: Plasminogen receptors: ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 2: 61–71, 1988

    Google Scholar 

  93. Pollanen J: Down-regulation of plasmin receptors on human sarcoma cells by glucocorticoids. J Biol Chem 264: 5628–5632, 1989

    Google Scholar 

  94. Stephens RW, Pollanen J, Tapiovaara H, Leung K-C, Sim P-S, Salonen E-M, Ronne E, Behrendt N, Dano K, Vaheri A: Activation of pro-urokinase and plasminogen on human sarcoma cells: A proteolytic system with surfacebound reactants. J Cell Biol 108: 1987–1995, 1989

    Google Scholar 

  95. Ellis V, Wun T-C, Behrendt N, Ronne E, Dano K: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J Biol Chem 265: 9904–9908, 1990

    Google Scholar 

  96. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F: Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 86: 4828–4823, 1989

    Google Scholar 

  97. Cubellis MV, Wun TC, Blasi F: Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9: 1079–1085, 1990

    Google Scholar 

  98. Estreicher A, Muhlhauser J, Carpentier J-L, Orci L, Vassalli J-D: The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783–792, 1990

    Google Scholar 

  99. Kirchheimer JC, Remold HG: Functional characteristics of receptor-bound urokinase on human monocytes: Catalytic efficiency and susceptibility to inactivation by plasminogen activator inhbitors. Blood 4: 1396–1402, 1989

    Google Scholar 

  100. Stoppelli MP, Mastronicola MR, Franco P, DeCesare D, Welinder K, Verdi P, Blasi F: Serine phosphorylation of biosynthetically labeled uPA from A431 human carcinoma cells. Resistance to PAI-1 inhibition. 4 suppl 3: 90, 1990

    Google Scholar 

  101. Petersen LC, Lund LR, Nielsen LS, Dano K, Skriver L: One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity, J Biol Chem 263: 11189–11195, 1988

    Google Scholar 

  102. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611–619, 1983

    Google Scholar 

  103. Kellen JA, Mirakian A, Kolin A: Antimetastatic effect of amiloride in an animal tumour model. Anticancer Res 8: 1373–1376, 1988

    Google Scholar 

  104. Ossowski L: Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52: 321–328, 1988

    Google Scholar 

  105. Hearing VJ, Law LW, Corti A, Appella E, Blasi F: Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270–1278, 1988

    Google Scholar 

  106. Schlechte W, Murano G, Boyd D: Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res 49: 6064–6069, 1989

    Google Scholar 

  107. Ossowski L: In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J Cell Biol 107: 2437–2445, 1988

    Google Scholar 

  108. Axelrod JH, Reich R, Miskin R: Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol Cell Biol 9: 2133–2141, 1989

    Google Scholar 

  109. Cajot J-F, Schleuning W-D, Medcalf RL, Bamat J, Testuz J, Liebermann L, Sordat: Mouse L cells expressing human prourokinase-type plasminogen activator: Effects on extracellular matrix degradation and invasion. J Cell Biol 109: 915–925, 1989

    Google Scholar 

  110. Furie B, Furie BC: The molecular basis of blood coagulation. Cell 53: 505–518, 1988

    Google Scholar 

  111. Flaumenhaft R, Moscatelli D, Saksela O, Rifkin DB: Role of extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 140: 75–81, 1989.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Pathology, State University of New York, 11794, Stony Brook, NY, USA

    J. E. Testa & J. P. Quigley

Authors
  1. J. E. Testa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. P. Quigley
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Testa, J.E., Quigley, J.P. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metast Rev 9, 353–367 (1990). https://doi.org/10.1007/BF00049524

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00049524

Key words

Search

Navigation